21世纪经济报道记者 雷若馨 深圳报道刚敲锣上市不到两个月的“港股多肽创新药第一股”，披露了最新药物进展。8月3日晚，麦科医药（02335.HK）发布自愿性公告，宣布其自主研发的注射用神经保护候选药物MT200605在治疗急性缺血性脑卒中（AIS）的II期临床试验中成功达到主要研究终点。全球疾病负担研究显示，2021年全球新发缺血性卒中（脑梗）约780万例。换算下来，每4秒，就有一人遭遇脑梗。而...
Source Link21世纪经济报道记者 雷若馨 深圳报道刚敲锣上市不到两个月的“港股多肽创新药第一股”，披露了最新药物进展。8月3日晚，麦科医药（02335.HK）发布自愿性公告，宣布其自主研发的注射用神经保护候选药物MT200605在治疗急性缺血性脑卒中（AIS）的II期临床试验中成功达到主要研究终点。全球疾病负担研究显示，2021年全球新发缺血性卒中（脑梗）约780万例。换算下来，每4秒，就有一人遭遇脑梗。而...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.